Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRASS 2: Preoperative chemotherapy versus surgery alone for high-risk retroperitoneal sarcoma
NL-OMON60618Phase 3Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dacarbazine, doxorubicin and ifosfamide in retroperitoneal liposarcoma (RLS) and retroperitoneal leiomyosarcoma (RLMS), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Disease-free survival. Started Sep 2021; status: recruiting.
02
Drugs
dacarbazinedoxorubicinifosfamide
03
Conditions
retroperitoneal liposarcoma (RLS)retroperitoneal leiomyosarcoma (RLMS)
Beyond the preview
Go deeper on NL-OMON60618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60618.